Cancer Immunotherapy Clinic
The UCSF Cancer Immunotherapy Clinic (CIC) provides cutting-edge treatments that harness a patient's own immune system to fight cancer. These include cancer vaccines, cellular therapies and other experimental drugs.
As the clinical arm of the UCSF Cancer Immunotherapy Program, the CIC benefits from a campus-wide network of physicians, nurses and laboratory scientists working in unison to discover better ways to treat cancer.
Lawrence H. Fong
Thomas G. Martin
MD, PhDMedical oncologist
Maryanne E. Christoforou
NP, MSNNurse practitioner
FNP, MSNNurse practitioner
RN, MSNNurse manager
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (C...
The primary objective of this access and distribution protocol is to examine the incidence of neutrophil recovery of ≥500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that are not FDA licensed.
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple M...
DLTs will be assessed during the DLT interval (ie, within 21 days immediately after bb2121 infusion). DLTs are defined as any bb2121 related Grade 3 to 5 toxicity.
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refrac...
Treatment-related Adverse events resulting in a DLT will be summarized by maximum toxicity grade for each dose level of isatuximab.
Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant...
Will be graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (version 5.0 beginning April 1, 2018). Safety and tolerability will be assessed by summarizing all relevant parameters including AEs, serious ...
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Adv...
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection ...
The dose limiting toxicities are based on drug related adverse events and defined as any of the following events: hematological or non-hematological toxicity of grade 3 or higher.
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malig...
Incidence of adverse events (AEs) observed across STRO-001 dose levels
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
Only patients in cohort 2, who achieve testosterone recovery to non-castrate levels (>150 ng/dL) at 15 months, will be analyzed for the primary endpoint. The rate of PSA < nadir + 2 ng/mL at 15 months from the start of radiotherap...
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Ca...
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refract...
ORR is defined as stringent complete response (sCR) + complete response (CR) + very good partial response + partial response (PR) as best response using International Myeloma Working Group (IMWG) Uniform Response Criteria for all ...
U.S. News rankings
Best hospital in Northern California
Best in Northern California in cancer care
Accreditations & memberships
National Cancer Institute
The National Cancer Institute has designated UCSF a comprehensive cancer center, its highest ranking. This designation is awarded to centers that demonstrate scientific excellence and the ability to conduct cancer research across many disciplines.
Commission on Cancer
UCSF's cancer programs have been accredited by the American College of Surgeons' Commission on Cancer (CoC) since 1933. The CoC is a consortium of groups dedicated to improving cancer patients' survival and quality of life via research, education and better medical care.
National Comprehensive Cancer Network
UCSF is a founding member of the National Comprehensive Cancer Network, an alliance of the world’s top cancer centers. The network brings together leaders in treatment and research to improve the quality, effectiveness and efficiency of cancer care.
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your condition
- List of your medications, including dosages, plus any you're allergic to
- List of questions you may have
- Device or paper for taking notes